Aenova Group Merges with Haupt Pharma
PAHL, Germany—Contract manufacturer and service provider Aenova Group is merging with Haupt Pharma, a German pharmaceutical company specializing in contract development and manufacturing. The move comes almost a year after Aenova took over the Temmler Group. The purchase price is confidential, and the agreement will be legally binding at the end of 2013.
"The strategic activities of both companies complement each other very well and this move gives us further areas of expertise strongly focusing on forward-looking sectors in the pharmaceutical market, which are a perfect fit with our existing portfolio," said Heiner Hoppmann, CEO of the Aenova Group, which recently debuted its VeganGel™ and EnteriGel™.
With the merger, Aenova's production network will increase from eight to 21 sites, including its first facility in Asia. The company's employee count will also grow from 2,500 to more than 4,000. The merger will add sterile manufacturing capabilities in addition to the production of special active ingredients.
The merger offers Haupt Pharma the opportunity to consolidate and continue its recent growth. The company's chairman of the supervisory board, Otto Prange, will accompany the enterprise as co-shareholder of the Aenova Group. Prange noted, ""The merger will increase our competitiveness in a challenging market and, as a result, make us significantly more attractive to our customers."
